About 35 years ago, I encountered several children and adolescents with acute lymphoblastic leukemia or widespread non-Hodgkin lymphoma who presented with or who developed, upon initiation of therapy, severe renal and metabolic derangements.
Peter F. Coccia, MD
Advertisement
Articles by Peter F. Coccia, MD
Advertisement
Latest Updated Articles
- The More Things Change, the More They Stay the Same
April 15th 2011
Advertisement
Advertisement
Trending on CancerNetwork
1
Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma
2
124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer
3
123 Real-World Patient and Caregiver Experiences With Breast Cancer (BC) Risk of Recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis
4
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
5